PRC2 Is Dispensable in Vivo for β-Catenin-Mediated Repression of Chondrogenesis in the Mouse Embryonic Cranial Mesenchyme.

Publisher: Oxford University Press Country of Publication: England NLM ID: 101566598 Publication Model: Electronic Cited Medium: Internet ISSN: 2160-1836 (Electronic) Linking ISSN: 21601836 NLM ISO Abbreviation: G3 (Bethesda) Subsets: MEDLINE

Publication: 2021- : [Oxford] : Oxford University Press
Original Publication: Bethesda, MD : Genetics Society of America, 2011-

Chondrogenesis/*genetics ; Mesoderm/*metabolism ; Polycomb Repressive Complex 2/*genetics ; Skull/*metabolism ; Wnt Signaling Pathway/*genetics ; beta Catenin/*genetics; Animals ; Cartilage/cytology ; Cartilage/embryology ; Cartilage/metabolism ; Cell Differentiation/genetics ; Enhancer of Zeste Homolog 2 Protein/genetics ; Enhancer of Zeste Homolog 2 Protein/metabolism ; Gene Expression Profiling/methods ; Gene Expression Regulation, Developmental ; Mesoderm/cytology ; Mesoderm/embryology ; Mice, Knockout ; Mice, Transgenic ; Polycomb Repressive Complex 2/metabolism ; Skull/cytology ; Skull/embryology ; beta Catenin/metabolism

A hallmark of craniofacial development is the differentiation of multiple cell lineages in close proximity to one another. The mouse skull bones and overlying dermis are derived from the cranial mesenchyme (CM). Cell fate selection of the embryonic cranial bone and dermis in the CM requires Wnt/β-catenin signaling, and loss of β-catenin leads to an ectopic chondrogenic cell fate switch. The mechanism by which Wnt/β-catenin activity suppresses the cartilage fate is unclear. Upon conditional deletion of β-catenin in the CM, several key determinants of the cartilage differentiation program, including Sox9 , become differentially expressed. Many of these differentially expressed genes are known targets of the Polycomb Repressive Complex 2 (PRC2). Thus, we hypothesized that PRC2 is required for Wnt/β-catenin-mediated repression of chondrogenesis in the embryonic CM. We find that β-catenin can physically interact with PRC2 components in the CM in vivo However, upon genetic deletion of Enhancer of Zeste homolog 2 (EZH2), the catalytic component of PRC2, chondrogenesis remains repressed and the bone and dermis cell fate is preserved in the CM. Furthermore, loss of β-catenin does not alter either the H3K27me3 enrichment levels genome-wide or on cartilage differentiation determinants, including Sox9 Our results indicate that EZH2 is not required to repress chondrogenesis in the CM downstream of Wnt/β-catenin signaling.
(Copyright © 2018 Ferguson et al.)

Nat Genet. 2007 Mar;39(3):311-8. (PMID: 17277777)
Nat Genet. 1999 Jan;21(1):70-1. (PMID: 9916792)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Mech Dev. 2008 Sep-Oct;125(9-10):797-808. (PMID: 18617001)
PLoS Genet. 2014 Feb 20;10(2):e1004152. (PMID: 24586192)
Cell. 2009 Dec 24;139(7):1290-302. (PMID: 20064375)
Mol Cell Neurosci. 2003 Nov;24(3):696-708. (PMID: 14664819)
Development. 2001 Apr;128(8):1253-64. (PMID: 11262227)
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6273-8. (PMID: 10339577)
Mol Cell Biol. 2002 Feb;22(4):1172-83. (PMID: 11809808)
Cell. 1997 May 30;89(5):755-64. (PMID: 9182763)
Nat Rev Cancer. 2006 Nov;6(11):846-56. (PMID: 17060944)
Nat Methods. 2012 Mar 04;9(4):357-9. (PMID: 22388286)
Nature. 2011 Jan 20;469(7330):343-9. (PMID: 21248841)
Dev Biol. 2006 Aug 1;296(1):164-76. (PMID: 16730693)
Development. 2015 Feb 15;142(4):722-31. (PMID: 25617436)
BMC Biol. 2015 Nov 30;13:103. (PMID: 26621269)
Mol Cell Biol. 2007 Jul;27(14 ):5105-19. (PMID: 17502350)
Genome Biol. 2013 Apr 25;14(4):R36. (PMID: 23618408)
Genes Dev. 2007 Nov 15;21(22):2923-35. (PMID: 18006687)
Genesis. 2016 Aug;54(8):415-30. (PMID: 27265328)
Bioinformatics. 2009 May 1;25(9):1105-11. (PMID: 19289445)
Nature. 2006 May 18;441(7091):349-53. (PMID: 16625203)
Am J Pathol. 2009 Sep;175(3):1246-54. (PMID: 19661437)
Mol Cell. 2013 Oct 24;52(2):193-205. (PMID: 24055345)
Mol Cell. 2008 Nov 21;32(4):491-502. (PMID: 19026780)
J Pathol. 2015 Apr;235(5):686-97. (PMID: 25385294)
Nat Biotechnol. 2013 Jan;31(1):46-53. (PMID: 23222703)
Cell. 2007 May 18;129(4):823-37. (PMID: 17512414)
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7317-22. (PMID: 20368440)
Bioinformatics. 2004 Nov 22;20(17):3246-8. (PMID: 15180930)
Nat Biotechnol. 2010 May;28(5):511-5. (PMID: 20436464)
Brief Bioinform. 2013 Mar;14(2):178-92. (PMID: 22517427)
J Orthop Res. 2017 May;35(5):1096-1105. (PMID: 27325507)
Genome Biol. 2011 Aug 11;12(8):R72. (PMID: 21835007)
J Neurochem. 2007 Jan;100(1):242-50. (PMID: 17064353)
J Biol Chem. 2015 Nov 13;290(46):27604-17. (PMID: 26424790)
Mol Cell Biol. 1998 Mar;18(3):1248-56. (PMID: 9488439)
Dev Dyn. 2016 Feb;245(2):144-56. (PMID: 26677825)
Nat Genet. 2007 Jul;39(7):836-8. (PMID: 17546030)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
Mol Cell. 2016 May 5;62(3):443-452. (PMID: 27151441)
Nucleic Acids Res. 2017 Sep 29;45(17 ):9901-9916. (PMID: 28973434)
Cell. 2006 Apr 21;125(2):301-13. (PMID: 16630818)
Mol Cell. 2014 Aug 7;55(3):347-60. (PMID: 24999238)
Nat Biotechnol. 2010 May;28(5):495-501. (PMID: 20436461)
Genome Biol. 2008;9(9):R137. (PMID: 18798982)
Nat Rev Cancer. 2016 Dec;16(12 ):803-810. (PMID: 27658528)
Development. 2010 Dec;137(23 ):3973-84. (PMID: 20980404)
Nat Commun. 2016 Nov 29;7:13685. (PMID: 27897169)
Development. 2014 Feb;141(4):867-77. (PMID: 24496623)
Nat Commun. 2016 Jun 22;7:12047. (PMID: 27329220)
Bioinformatics. 2013 Dec 1;29(23):3097-9. (PMID: 24008416)
Nat Biotechnol. 2011 Jan;29(1):24-6. (PMID: 21221095)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Genome Biol. 2011;12(3):R22. (PMID: 21410973)
Development. 1995 Nov;121(11):3529-37. (PMID: 8582267)
J Bone Miner Res. 2013 May;28(5):1050-60. (PMID: 23225119)
Curr Opin Cell Biol. 2004 Jun;16(3):239-46. (PMID: 15145347)
Int J Dev Biol. 2002;46(4):401-13. (PMID: 12141426)
Dev Biol. 2002 Jan 1;241(1):106-16. (PMID: 11784098)
Nature. 2009 May 7;459(7243):108-12. (PMID: 19295514)
Proc Natl Acad Sci U S A. 2011 May 31;108(22):E149-58. (PMID: 21551099)
Bioinformatics. 2011 Sep 1;27(17):2325-9. (PMID: 21697122)
Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15782-7. (PMID: 17043231)
Cell Rep. 2017 Mar 21;18(12 ):2815-2824. (PMID: 28329675)
J Biol Chem. 2010 Jan 1;285(1):317-27. (PMID: 19858186)
Genome Res. 2003 Sep;13(9):2129-41. (PMID: 12952881)
BMC Genomics. 2014 Apr 15;15:284. (PMID: 24735413)
PLoS Genet. 2010 Jun 10;6(6):e1000977. (PMID: 20548944)
Development. 2008 Jul;135(13):2321-9. (PMID: 18539925)
Genes Dev. 2000 Jun 1;14(11):1377-89. (PMID: 10837030)
Hum Mol Genet. 1997;6(10 ):1647-56. (PMID: 9300656)
Nature. 1996 Jul 18;382(6588):225-30. (PMID: 8717036)
Development. 2003 Jul;130(13):3063-74. (PMID: 12756187)
Cell Rep. 2014 Sep 11;8(5):1419-31. (PMID: 25159139)
Science. 2017 Mar 31;355(6332):. (PMID: 28360266)
Development. 2012 Dec 1;139(23 ):4428-38. (PMID: 23095887)

R01 DE018470 United States DE NIDCR NIH HHS; R01 AR068308 United States AR NIAMS NIH HHS; R01 CA160356 United States CA NCI NIH HHS; T32 AR007505 United States AR NIAMS NIH HHS; R01 AR046249 United States AR NIAMS NIH HHS; R01 CA193677 United States CA NCI NIH HHS

Keywords: H3K27me3; cell fate selection; cranial dermis; development; skull bone

0 (beta Catenin)
EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
EC 2.1.1.43 (Polycomb Repressive Complex 2)

Date Created: 20171211 Date Completed: 20181011 Latest Revision: 20181113

20231215

PMC5919733

10.1534/g3.117.300311

29223978